IDEXX Laboratories (NASDAQ:IDXX) Stock Rating Lowered by Wall Street Zen

Key Points

• IDEXX was downgraded by Wall Street Zen from a "buy" to a "hold" and several brokers have trimmed price targets, though the consensus remains a "Moderate Buy" with a $760 average price target.
• The company reported an EPS beat ($3.08 vs. $2.93 expected) and revenue of $1.09B (up 14.3% year-over-year) and set FY2026 guidance of $14.29–$14.80 EPS (sell-side expects $14.54).
• Insider selling has been notable recently: CEO Jonathan Mazelsky sold 23,326 shares (~$15.34M) and insiders sold 45,957 shares totaling about $29.9M over the last three months, while corporate insiders still own 0.79% of shares.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Saturday.

IDXX has been the topic of several other research reports. BTIG Research cut their target price on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating on the stock in a research note on Tuesday, February 3rd. UBS Group cut their target price on IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 3rd. Piper Sandler cut their target price on IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a research note on Monday, February 9th. Citigroup assumed coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a "neutral" rating and a $650.00 target price on the stock. Finally, Weiss Ratings cut IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Thursday, January 29th. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $760.00.

IDEXX Laboratories Trading Up 0.9%

NASDAQ IDXX opened at $565.93 on Friday. The firm has a market cap of $44.95 billion, a P/E ratio of 43.30, a P/E/G ratio of 3.41 and a beta of 1.72. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The stock's 50-day moving average is $594.81 and its 200-day moving average is $652.81. IDEXX Laboratories has a one year low of $427.70 and a one year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, February 2nd. The company reported $3.08 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.15. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.IDEXX Laboratories's revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts anticipate that IDEXX Laboratories will post 14.54 earnings per share for the current fiscal year.

Insider Activity

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the business's stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the transaction, the chief executive officer owned 83,606 shares of the company's stock, valued at $54,975,125.30. The trade was a 21.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Sophie V. Vandebroek sold 1,464 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the transaction, the director directly owned 648 shares in the company, valued at $407,345.76. This trade represents a 69.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 45,957 shares of company stock worth $29,862,109. Corporate insiders own 0.79% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. SHP Wealth Management acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $26,000. Virtus Advisers LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $26,000. Park Place Capital Corp acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $29,000. WealthCollab LLC acquired a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $30,000. Finally, J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $31,000. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.